Document Classification

Section Type: RESULTS

Text: Median progression-free survival and overall survival times were 3. 2 months (95 % CI, 1. 8 to 4. 6 months) and 6. 8 months (95 % CI, 2. 6 to 11. 1 months) with LV5FU2, respectively ; 4. 9 months (95 % CI, 3. 5 to 6. 3 months) and 9. 5 months (95 % CI, 6. 9 to 12. 2 months) with LV5FU2-cisplatin, respectively ; and 6. 9 months (95 % CI, 5. 5 to 8. 3 months) and 11. 3 months (95 % CI, 9. 3 to 13. 3 months) with LV5FU2-irinotecan, respectively.